Literature DB >> 3491165

Immunity to Haemophilus influenzae type b in young adults: correlation of bactericidal and opsonizing activity of serum with antibody to polyribosylribitol phosphate and lipooligosaccharide before and after vaccination.

D Musher, A Goree, T Murphy, A Chapman, J Zahradnik, M Apicella, R Baughn.   

Abstract

Naturally acquired humoral immunity is thought to protect adults against serious infections due to Haemophilus influenzae type b (Hib). Antibody to the polyribosylribitol phosphate (PRP) capsule is generally considered protective; antibody to lipooligosaccharide (LOS) or outer membrane protein (OMP) may also play a role. Serum from 23 of 50 healthy young adults had no bactericidal effect (BE) against Hib yet opsonized these organisms for approximately 30% uptake by polymorphonuclear leukocytes. The degree of bactericidal and opsonizing activity in serum from the other 27 subjects generally correlated with the level of antibody to PRP but not to LOS or OMP. However, serum from some individuals had levels of antibody to PRP as high as 4.9 micrograms/ml without BE, and seven of 27 subjects with BE had antibody levels of less than 1 microgram/ml. After vaccination with 20 micrograms of conjugated PRP, the level of antibody to PRP was greater than 5 micrograms/ml in all 50 subjects. BE appeared in 22 of those who originally lacked it, and opsonization increased to approximately 50%.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3491165     DOI: 10.1093/infdis/154.6.935

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG.

Authors:  B Selander; H Käyhty; E Wedege; E Holmström; L Truedsson; C Söderström; A G Sjöholm
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

2.  Complement component 3 binding to Haemophilus influenzae type b in the presence of anticapsular and anti-outer membrane antibodies.

Authors:  S V Hetherington; C C Patrick
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

3.  Antibody to the outer membrane proteins is the dominant opsonic antibody in normal human serum against H. influenzae type b.

Authors:  S V Hetherington
Journal:  Immunology       Date:  1989-05       Impact factor: 7.397

4.  Role of complement in mouse macrophage binding of Haemophilus influenzae type b.

Authors:  G J Noel; D M Mosser; P J Edelson
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

5.  Comparison of naturally acquired and vaccine-induced antibodies to Haemophilus influenzae type b capsular polysaccharide.

Authors:  M T Jelonek; S J Chang; C Y Chiu; M K Park; M H Nahm; J I Ward
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

6.  Serum antibody response to capsular polysaccharide, outer membrane, and lipooligosaccharide in children with invasive Haemophilus influenzae type b infections.

Authors:  B A Claesson; T Lagergård; B Trollfors; L Gothefors; U Jodal
Journal:  J Clin Microbiol       Date:  1987-12       Impact factor: 5.948

7.  Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines.

Authors:  Philippe A Denoël; David Goldblatt; Isabel de Vleeschauwer; Jeanne-Marie Jacquet; Michael E Pichichero; Jan T Poolman
Journal:  Clin Vaccine Immunol       Date:  2007-08-15

8.  Functional capacities of clonal antibodies to Haemophilus influenzae type b polysaccharide.

Authors:  M H Nahm; K H Kim; P Anderson; S V Hetherington; M K Park
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

Review 9.  Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria.

Authors:  Manish Sadarangani
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.